ClinicalTrials.gg
RecruitingNCT02038127GWPCIUpdated Oct 7, 2026

Gangwon PCI Prospective Registry

An observational study in Coronary Artery Disease, Ischemic Heart Disease (IHD) and Unstable Angina (UA), sponsored by Yonsei University. Recruiting at 4 sites in South Korea. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by Yonsei University · Observational

How we know

From the registry’s dates

  • Started Jan 2013; still recruiting 13 years 10 months later.
Updated Oct 7, 2026Site recruiting status changedEnrollment updated+6 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
10,000
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 64 studies in Coronary Artery Disease by Yonsei University — 13 open to participants now, 18 under way, none of them phase 3. Coronary Artery Disease · Yonsei University.

Planned enrollment
3rd of 26
10,000 · median 300
Started
2013
with 3 others
Observational
26 of 64
6 open now
Primary completion
2030-12
later than 14 of 17 live
Registered
18th of 64
by date

Among the 64 studies in Coronary Artery Disease by Yonsei University, this one is the 3rd largest by planned enrollment of the 26 observational ones that give a count, is one of 4 that started in 2013, is one of 26 observational ones, reaches primary completion later than 14 of the 17 other live ones, and was the 18th registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

13 of the 64 studies in Coronary Artery Disease by Yonsei University are open now, in 1 country. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 13 open studies →

Where they have run

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies in Coronary Artery Disease by Yonsei University, or all of them as a file.
02

Study summary

This prospective, multicenter registry will consecutively enroll patients of all ages undergoing percutaneous coronary intervention (PCI) at four university hospitals in Gangwon Province, Republic of Korea.

The study will describe contemporary clinical, procedural, and medication treatment patterns and assess 1-year clinical outcomes in routine practice.

The primary outcome is patient-oriented composite outcome (POCO), defined as all-cause death, any myocardial infarction, or any repeat revascularization.

No study-specific intervention will be assigned.

Read the detailed description

This prospective, multicenter, observational registry will consecutively enroll patients of all ages undergoing percutaneous coronary intervention (PCI) at four university hospitals in Gangwon Province, Republic of Korea.

The registry is designed to provide real-world data on the clinical characteristics, angiographic findings, procedural strategies, and pharmacological treatment patterns of patients treated with PCI.

PCI and all subsequent medical care will be performed according to routine clinical practice and at the discretion of the treating physicians. The study will not mandate any diagnostic test, procedural strategy, device, or medication.

Baseline clinical characteristics, cardiovascular risk factors, laboratory findings, angiographic and lesion characteristics, procedural details, in-hospital events, discharge medications, and follow-up clinical outcomes will be prospectively recorded.

For patients undergoing staged PCI during the same hospitalization, information on the initial and subsequent procedures will be recorded separately using dedicated electronic case report forms.

Clinical outcomes will be assessed for 1 year after PCI through review of medical records, outpatient follow-up, and telephone contact.

The primary outcome is patient-oriented composite outcome (POCO), defined as all-cause death, any myocardial infarction, or any repeat revascularization. The registry will evaluate the incidence of POCO and examine its associations with baseline clinical, angiographic, procedural, and treatment-related characteristics.

03

Conditions studied

  • Coronary Artery Disease
  • Ischemic Heart Disease (IHD)
  • Unstable Angina (UA)
  • Non-ST Elevated Myocardial Infarction
  • ST-Elevation Myocardial Infarction
  • Vasospastic Angina

Keywords

  • Percutaneous Coronary Intervention (PCI)
  • Coronary Artery Disease
  • Prospective Multicenter Registry
  • Clinical Outcomes
04

Who can participate

The criteria were revised on the registry on Oct 7, 2026. See what changed

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population will consist of consecutive, all-comer patients of any age undergoing percutaneous coronary intervention (PCI) at four participating university hospitals in Gangwon Province, Republic of Korea.

Patients undergoing PCI for any clinical presentation, including chronic coronary syndrome and acute coronary syndrome, will be eligible. There will be no restrictions based on sex, clinical presentation, comorbidity, lesion complexity, or procedural characteristics.

Patients undergoing staged PCI during the same hospitalization will be included. Information on the initial and subsequent procedures will be recorded separately using dedicated electronic case report forms.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients of any age undergoing percutaneous coronary intervention (PCI) at a participating hospital during the study period.
  • Written is obtained from the patient or a legally authorized representative before collection of study data, unless the requirement for informed consent is waived by the Institutional Review Board.

Exclusion criteria

Exclusion Criteria:

  • Refusal or withdrawal of , when informed consent is required.
  • No PCI performed during the index hospital encounter.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
10,000 participants (estimated)
Target follow-up
3 Years
Patient registry
Yes

Groups and cohorts

  • Patients undergoing PCI

    All consecutively enrolled patients undergoing percutaneous coronary intervention at the participating hospitals. PCI is performed as part of routine clinical care and is not assigned by the study protocol.

    Procedure: Percutaneous Coronary Intervention (PCI)

Interventions

  • ProcedurePercutaneous Coronary Intervention (PCI)

    PCI performed as part of routine clinical care; no study-specific procedure is assigned.

06

What researchers measure

Primary outcomes

  1. Patient-oriented composite outcome (POCO)

    A composite of all-cause death, any myocardial infarction, or any repeat revascularization.

    Time frame: Within 1 year after the index PCI procedure

Secondary outcomes

  1. Device-oriented composite outcome (DOCO)

    A composite of cardiac death, target-vessel myocardial infarction, and clinically indicated target lesion revascularization.

    Time frame: Within 1 year after the index PCI procedure

  2. All-cause death

    Death from any cause

    Time frame: Within 1 year after the index PCI procedure

  3. Cardiovascular death

    Death resulting from a cardiovascular cause.

    Time frame: Within 1 year after the index PCI procedure

  4. Any myocardial infarction

    Any myocardial infarction occurring after the index PCI procedure.

    Time frame: Within 1 year after the index PCI procedure

  5. Target-vessel myocardial infarction

    Myocardial infarction attributable to the coronary vessel treated during the index PCI procedure.

    Time frame: Within 1 year after the index PCI procedure

  6. Clinically indicated Target vessel revascularization (TVR)

    Repeat percutaneous coronary intervention or coronary artery bypass grafting of any segment of the target vessel, including the target lesion, when clinically indicated.

    Time frame: Within 1 year after the index PCI procedure

  7. Clinically indicated Target vessel revascularization (TVR)

    Repeat percutaneous coronary intervention of the target lesion or coronary artery bypass grafting of the target vessel for restenosis or another complication of the target lesion, when clinically indicated. The target lesion includes the treated segment and the 5-mm margins proximal and distal to the implanted stent.

    Time frame: Within 1 year after the index PCI procedure

  8. Any repeat revascularization

    Any repeat coronary revascularization, including repeat PCI or coronary artery bypass grafting.

    Time frame: Within 1 year after the index PCI procedure

  9. Definite or probable stent thrombosis

    Definite or probable stent thrombosis according to the Academic Research Consortium criteria.

    Time frame: Within 1 year after the index PCI procedure

  10. Major bleeding

    Major bleeding defined as Bleeding Academic Research Consortium (BARC) type 3 or 5 bleeding.

    Time frame: Within 1 year after the index PCI procedure

07

Study locations

4 of 4 sites recruiting
  • Chuncheon Hallym University Hospital
    Chuncheon, Gangwon-do 24253, South Korea
    Recruiting
    • Hyun Hee Choi, M.D. · Contactjumdure@hanmail.net · 82-33-240-5000
    • Hyun Hee Choi, M.D. · Principal investigator
  • Kangwon National University Hospital
    Chuncheon, Gangwon-do 24289, South Korea
    Recruiting
    • Bong-Ki Lee, M.D., Ph.D. · Contactmdbklee@kangwon.ac.kr · 82-33-258-2000
    • Cheol Ung Choi, M.D., Ph.D. · Principal investigator
  • Gangneung Asan Hospital
    Gangneung, Gangwon-do 25440, South Korea
    Recruiting
  • Wonju Severance Christian Hospital
    Wŏnju, Gangwon-do 26426, South Korea
    Recruiting
    • Young Jin Youn, M.D., Ph.D. · Contactyounyj@yonsei.ac.kr · +82-33-741-0917
    • Young Jin Youn, M.D., Ph.D. · Principal investigator
    • Sung Gyun Ahn, M.D., Ph.D. · Sub investigator
    • Jun-Won Lee, M.D., Ph.D. · Sub investigator
    • Jung-Hee Lee, M.D., Ph.D. · Sub investigator
    • Ho Sung Jeon, M.D. · Sub investigator
    • Su Yong Kim, M.D. · Sub investigator
08

References and documents

Publications

  • Jeon HS, Youn YJ, Lee JH, Park YJ, Son JW, Lee JW, Ahn MS, Ahn SG, Kim JY, Yoo BS, Yoon J. Safety and Efficacy of Two Ultrathin Biodegradable Polymer Sirolimus-Eluting Stents in Real-World Practice: Genoss DES Stents Versus Orsiro Stents From a Prospective Registry. Clin Cardiol. 2024 Dec;47(12):e70060. doi: 10.1002/clc.70060. PubMed 39691038 ↗
  • Jeon HS, Kim YI, Lee JH, Park YJ, Son JW, Lee JW, Youn YJ, Ahn MS, Kim JY, Yoo BS, Ko SM, Ahn SG. Failed Thrombus Aspiration and Reduced Myocardial Perfusion in Patients With STEMI and Large Thrombus Burden. JACC Cardiovasc Interv. 2024 Oct 14;17(19):2216-2225. doi: 10.1016/j.jcin.2024.07.016. Epub 2024 Sep 18. PubMed 39297854 ↗
  • Youn YJ, Jeon HS, Kim YI, Lee JH, Park YJ, Cho DH, Son JW, Lee JW, Ahn MS, Ahn SG, Kim JY, Yoo BS, Lee SH, Yoon J. Impact of the ultra-long 48 mm drug-eluting stent on procedural and clinical outcomes in patients with diffuse long coronary artery disease. Clin Cardiol. 2023 Apr;46(4):416-424. doi: 10.1002/clc.23997. Epub 2023 Feb 20. PubMed 36807273 ↗

Individual participant data

Plan to share: No — Individual participant data will not be shared because the multicenter registry contains potentially identifiable clinical data, and no data-sharing governance framework has been established among the participating institutions.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2013 (actual). Primary completion is estimated for Dec 2030, 215 months after the start.

Of 637 non-industry observational studies under Coronary Artery Disease, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 122. This study's planned 215 months is above that.

Counting every sponsor, half of 762 studies reached it within 41 months; a quarter within 21 and three quarters within 87.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 14, 2014
First posted
Jan 16, 2014
StartActual
Jan 1, 2013
Primary completionEst.
Dec 31, 2030
CompletionEst.
Dec 31, 2031
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
3 sites added, 2 sites removed. Chuncheon Hallym University Hospital is now Recruiting
Show 3 added (3 South Korea)
  • Kangwon National University Hospital · Chuncheon, South Korea
  • Gangneung Asan Hospital · Gangneung, South Korea
  • Wonju Severance Christian Hospital · Wŏnju, South Korea
Show 2 removed
  • Yonsei University Wonju Christian Hospital · Wŏnju, South Korea
  • Korea University Guro Hospital · Seoul, South Korea
Oct 7, 2026
Enrollment
5000→10000
Oct 7, 2026
Eligibility
Minimum age 19 Years→none; Criteria largely rewritten (15 changes)
What changed in the criteria
Inclusion criteria
  • RemovedAge > 19 years
  • RemovedSubject is able to verbally confirm understanding of risks, benefits and treatment alternatives of receiving the drug-eluting stent(s) and he/she or his/her legally authorized representative provides written informed consent prior to any study related procedure
  • RemovedSubject must have significant stenosis (>50% by visual estimate) on a native or in-stent coronary artery
  • RemovedSubject must have evidence of myocardial ischemia (e.g., stable, unstable angina, recent infarction, acute myocardial infarction, positive functional study or a reversible changes in the ECG consistent with ischemia). In subjects with coronary artery stenosis >75%, evidence of myocardial ischemia does not have to be documented
  • AddedPatients of any age undergoing percutaneous coronary intervention (PCI) at a participating hospital during the study period.
  • AddedWritten informed consent is obtained from the patient or a legally authorized representative before collection of study data, unless the requirement for informed consent is waived by the Institutional Review Board.
Exclusion criteria
  • RemovedSubject has a known hypersensitivity or contraindication to any of the following medications: heparin, aspirin, clopidogrel, prasugrel, ticagrelor, biolimus A9, everolimus, zotarolimus, stainless steel, cobalt chromium, contrast media (Patients with documented sensitivity to contrast media, which can be effectively premedicated with steroid and diphenhydramine may be enrolled. However, those with true anaphylaxis to prior contrast media should not be enrolled.)
  • RemovedSubject in use of systemic (intravenous) biolimus A9, everolimus or zotarolimus within 12 months.
  • RemovedFemale subject of childbearing potential, unless a recent pregnancy test is negative, who possibly plans to become pregnant any time after enrollment into this study
  • RemovedSubject planned an elective surgical procedure that would necessitate interruption of antiplatelet during the first 12 months post enrollment
  • RemovedSubject with non-cardiac co-morbid condition with life expectancy < 2 year or that may result in protocol non-compliance (per site investigator's medical judgment)
  • RemovedSubject with cardiogenic shock at presentation
  • RemovedSubject who are actively participating in another drug or device investigational study, who have not completed the primary end point follow-up period
  • AddedRefusal or withdrawal of informed consent, when informed consent is required.
  • AddedNo PCI performed during the index hospital encounter.
Oct 7, 2026
Interventions
Arms or interventions changed
Oct 7, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedDevicePatient-oriented composite outcome (POCO)Time frame: 24 months → Within 1 year after the index PCI procedure
Oct 7, 2026
Secondary outcomes
3 edited, 7 added, 2 removed
What changed in the outcomes
  • EditedPatientDevice-oriented composite outcome (DOCO)Time frame: 24 months → Within 1 year after the index PCI procedure
  • EditedTarget -vessel revascularizationmyocardial infarctionTime frame: 12 months → Within 1 year after the index PCI procedure
  • EditedClinically indicated Target vessel revascularization (TVR)Time frame: 24 months → Within 1 year after the index PCI procedure
  • AddedAll-cause deathTime frame: Within 1 year after the index PCI procedure
  • AddedCardiovascular deathTime frame: Within 1 year after the index PCI procedure
  • AddedAny myocardial infarctionTime frame: Within 1 year after the index PCI procedure
  • AddedClinically indicated Target vessel revascularization (TVR)Time frame: Within 1 year after the index PCI procedure
  • AddedAny repeat revascularizationTime frame: Within 1 year after the index PCI procedure
  • AddedDefinite or probable stent thrombosisTime frame: Within 1 year after the index PCI procedure
  • AddedMajor bleedingTime frame: Within 1 year after the index PCI procedure
  • RemovedARC defined stent thrombosisTime frame: 12 months
  • RemovedARC defined stent thrombosisTime frame: 24 months
Oct 7, 2026
Contact
Study contact changed: j•••@yonsei.ac.kr · •••0906→y•••@yonsei.ac.kr · •••0917; y•••@yonsei.ac.kr · •••0917→l•••@yonsei.ac.kr · •••0920. See the current contact
Oct 7, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Chuncheon Hallym University Hospital · Chuncheon, South KoreaContact none listed→•••5000
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    3 sites added, 2 sites removed. Chuncheon Hallym University Hospital is now Recruiting
    Show 3 added (3 South Korea)
    • Kangwon National University Hospital · Chuncheon, South Korea
    • Gangneung Asan Hospital · Gangneung, South Korea
    • Wonju Severance Christian Hospital · Wŏnju, South Korea
    Show 2 removed
    • Yonsei University Wonju Christian Hospital · Wŏnju, South Korea
    • Korea University Guro Hospital · Seoul, South Korea
    Enrollment 5000→10000
    Eligibility Minimum age 19 Years→none; Criteria largely rewritten (15 changes)
    What changed in the criteria
    Inclusion criteria
    • RemovedAge > 19 years
    • RemovedSubject is able to verbally confirm understanding of risks, benefits and treatment alternatives of receiving the drug-eluting stent(s) and he/she or his/her legally authorized representative provides written informed consent prior to any study related procedure
    • RemovedSubject must have significant stenosis (>50% by visual estimate) on a native or in-stent coronary artery
    • RemovedSubject must have evidence of myocardial ischemia (e.g., stable, unstable angina, recent infarction, acute myocardial infarction, positive functional study or a reversible changes in the ECG consistent with ischemia). In subjects with coronary artery stenosis >75%, evidence of myocardial ischemia does not have to be documented
    • AddedPatients of any age undergoing percutaneous coronary intervention (PCI) at a participating hospital during the study period.
    • AddedWritten informed consent is obtained from the patient or a legally authorized representative before collection of study data, unless the requirement for informed consent is waived by the Institutional Review Board.
    Exclusion criteria
    • RemovedSubject has a known hypersensitivity or contraindication to any of the following medications: heparin, aspirin, clopidogrel, prasugrel, ticagrelor, biolimus A9, everolimus, zotarolimus, stainless steel, cobalt chromium, contrast media (Patients with documented sensitivity to contrast media, which can be effectively premedicated with steroid and diphenhydramine may be enrolled. However, those with true anaphylaxis to prior contrast media should not be enrolled.)
    • RemovedSubject in use of systemic (intravenous) biolimus A9, everolimus or zotarolimus within 12 months.
    • RemovedFemale subject of childbearing potential, unless a recent pregnancy test is negative, who possibly plans to become pregnant any time after enrollment into this study
    • RemovedSubject planned an elective surgical procedure that would necessitate interruption of antiplatelet during the first 12 months post enrollment
    • RemovedSubject with non-cardiac co-morbid condition with life expectancy < 2 year or that may result in protocol non-compliance (per site investigator's medical judgment)
    • RemovedSubject with cardiogenic shock at presentation
    • RemovedSubject who are actively participating in another drug or device investigational study, who have not completed the primary end point follow-up period
    • AddedRefusal or withdrawal of informed consent, when informed consent is required.
    • AddedNo PCI performed during the index hospital encounter.
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedDevicePatient-oriented composite outcome (POCO)Time frame: 24 months → Within 1 year after the index PCI procedure
    Secondary outcomes 3 edited, 7 added, 2 removed
    What changed in the outcomes
    • EditedPatientDevice-oriented composite outcome (DOCO)Time frame: 24 months → Within 1 year after the index PCI procedure
    • EditedTarget -vessel revascularizationmyocardial infarctionTime frame: 12 months → Within 1 year after the index PCI procedure
    • EditedClinically indicated Target vessel revascularization (TVR)Time frame: 24 months → Within 1 year after the index PCI procedure
    • AddedAll-cause deathTime frame: Within 1 year after the index PCI procedure
    • AddedCardiovascular deathTime frame: Within 1 year after the index PCI procedure
    • AddedAny myocardial infarctionTime frame: Within 1 year after the index PCI procedure
    • AddedClinically indicated Target vessel revascularization (TVR)Time frame: Within 1 year after the index PCI procedure
    • AddedAny repeat revascularizationTime frame: Within 1 year after the index PCI procedure
    • AddedDefinite or probable stent thrombosisTime frame: Within 1 year after the index PCI procedure
    • AddedMajor bleedingTime frame: Within 1 year after the index PCI procedure
    • RemovedARC defined stent thrombosisTime frame: 12 months
    • RemovedARC defined stent thrombosisTime frame: 24 months
    Interventions Arms or interventions changed
    Contact Study contact changed: j•••@yonsei.ac.kr · •••0906→y•••@yonsei.ac.kr · •••0917; y•••@yonsei.ac.kr · •••0917→l•••@yonsei.ac.kr · •••0920. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Chuncheon Hallym University Hospital · Chuncheon, South KoreaContact none listed→•••5000
    + 8 other changes: verification date, responsible party, oversight details, description, conditions, design details, data sharing statement and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT02038127
Lead sponsor
Yonsei University
Collaborators
Gangwon Cardiovascular Health Research Institute
Responsible party
Young Jin Youn, MD, PhD (Professor, Yonsei University) — Principal investigator
First posted
Jan 16, 2014
Start date
Jan 1, 2013
Primary completion
Dec 31, 2030 (estimated)
Completion
Dec 31, 2031 (estimated)
Last update
Oct 7, 2026

Study contacts

Young Jin Youn, M.D., Ph.D.
Contact
younyj@yonsei.ac.kr
+82-33-741-0917
Jun-Won Lee, M.D., Ph.D.
Contact
ljwcardio@yonsei.ac.kr
+82-33-741-0920
Young Jin Youn, M.D., Ph.D.
principal investigator · Yonsei University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion